Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,385,814
  • Shares Outstanding, K 54,960
  • Annual Sales, $ 5,420 K
  • Annual Income, $ -267,270 K
  • 36-Month Beta 1.24
  • Price/Sales 414.92
  • Price/Cash Flow 0.00
  • Price/Book 5.24

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.36 +35.82%
on 06/28/17
44.24 -0.66%
on 07/24/17
+8.93 (+25.50%)
since 06/23/17
3-Month
28.82 +52.50%
on 05/31/17
44.24 -0.66%
on 07/24/17
+9.93 (+29.19%)
since 04/24/17
52-Week
23.28 +88.79%
on 07/26/16
63.73 -31.04%
on 09/28/16
+20.06 (+83.97%)
since 07/22/16

Most Recent Stories

More News
Sarepta Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular...

SRPT : 43.95 (+1.24%)
25.8% Return Seen to Date on SmarTrend Sarepta Therapeu Call (SRPT)

SmarTrend identified an Uptrend for Sarepta Therapeu (NASDAQ:SRPT) on June 21st, 2017 at $34.53. In approximately 1 month, Sarepta Therapeu has returned 25.79% as of today's recent price of $43.43.

SRPT : 43.95 (+1.24%)
Sarepta Therapeu is Among the Companies in the Biotechnology Industry with the Best Relative Performance (SRPT, ONCE, RXDX, PTCT, CYTK)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

PTCT : 21.55 (+0.51%)
CYTK : 14.40 (-0.69%)
ONCE : 74.01 (+7.23%)
SRPT : 43.95 (+1.24%)
RXDX : 9.35 (+0.54%)
After Yesterday's Rally of 5.30% Shares Could Potentially Pullback

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $41.49 to a high of $44.07. Yesterday, the shares gained 5.3%, which took the trading range above the 3-day high...

SRPT : 43.95 (+1.24%)
Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why

On Thursday, shares of Sarepta Therapeutics (SRPT) are surging, up almost 24% to $42.14 per share in morning trading after the biotech company reported second-quarter revenues that blew past expectations...

SRPT : 43.95 (+1.24%)
BMRN : 90.01 (+0.82%)
Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View

Increase in Exondys 51 sales led Sarepta (SRPT) to post a narrower-than-expected loss in the second quarter of 2017.

SRPT : 43.95 (+1.24%)
SMMT : 12.60 (-0.71%)
VRTX : 166.11 (+1.80%)
BMRN : 90.01 (+0.82%)
Sarepta & BioMarin Settle Patent Litigation on Exon Skipping

Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies....

ENZ : 11.30 (-0.44%)
SRPT : 43.95 (+1.24%)
BMRN : 90.01 (+0.82%)
SNY : 47.71 (unch)
Investor Network: Sarepta Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / July 19, 2017 / Sarepta Therapeutics, Inc. (NASDAQ: SRPT) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, July 19, 2017 at 4:30...

SRPT : 43.95 (+1.24%)
Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs

Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.

SRPT : 43.95 (+1.24%)
PBYI : 95.85 (+1.64%)
VRTX : 166.11 (+1.80%)
GILD : 74.39 (+0.85%)
AMGN : 181.06 (+0.47%)
ALXN : 130.74 (-0.80%)
BIIB : 284.70 (+0.63%)
Sarepta Therapeutics and Clinigen Launch a Managed Access Program to Treat Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases,...

SRPT : 43.95 (+1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Support & Resistance

2nd Resistance Point 45.47
1st Resistance Point 44.71
Last Price 43.95
1st Support Level 42.72
2nd Support Level 41.49

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.